Effects of the 5-HT2A Antagonist Sarpogrelate on Walking Ability in Patients with Intermittent Claudication As Measured Using the Walking Impairment Questionnaire

Overview

Journal Ann Vasc Dis

Specialty Cardiology & Vascular Diseases

Date 2013 Apr 5

PMID 23555346

Citations 2

Authors

Hiroshi Matsuo

Hiroshi Shigematsu

Affiliations

Soon will be listed here.

Abstract

Background: The Walking Impairment Questionnaire (WIQ) measures walking ability in daily life in patients with peripheral arterial disease causing intermittent claudication. We investigated the efficacy of sarpogrelate, a 5-HT2A receptor antagonist, in improving walking ability, as measured using new Japanese version of the WIQ.

Patients And Methods: A nationwide multicenter study was conducted at 80 institutions in Japan involving 586 patients with stable symptoms of intermittent claudication. Patients received open-label sarpogrelate 300 mg/day. A total of 419 patients were evaluated in the full analysis set (FAS) following the intention to treat principle, and 354 patients were evaluated in the per-protocol set (PPS). The FAS data are emphasized here.

Results: The mean follow-up was 27.7 ± 10.1 weeks. Each subscale of the WIQ score showed improvement after sarpogrelate treatment (p < 0.0001), and the resting ankle-brachial index increased significantly (p < 0.0001). The incidence of adverse reactions of the entire series of 559 patients was 4.83% (27 patients), but there were no clinically significant safety concerns.

Conclusions: We have for the first time demonstrated that sarpogrelate may improve walking ability in daily life in Japanese patients with intermittent claudication. The drug had a good safety profile.

Citing Articles

The Effect of Hachimi-Jio-Gan (Ba-Wei-Di-Huang-Wan) on the Quality of Life in Patients with Peripheral Arterial Disease - A Prospective Study Using Kampo Medicine.

Kawago K, Shindo S, Inoue H, Akasaka J, Motohashi S, Urabe G Ann Vasc Dis. 2016; 9(4):289-294.

PMID: 28018500 PMC: 5174988. DOI: 10.3400/avd.oa.15-00133.

Comprehensive Proteome Profiling of Platelet Identified a Protein Profile Predictive of Responses to An Antiplatelet Agent Sarpogrelate.

Lee H, Chae S, Park J, Bae J, Go E, Kim S Mol Cell Proteomics. 2016; 15(11):3461-3472.

PMID: 27601597 PMC: 5098043. DOI: 10.1074/mcp.M116.059154.

References

Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R . Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost. 2006; 4(1):247-55. DOI: 10.1111/j.1538-7836.2005.01702.x. View

Barletta G, Perna S, Sabba C, Catalano A, OBoyle C, Brevetti G . Quality of life in patients with intermittent claudication: relationship with laboratory exercise performance. Vasc Med. 1996; 1(1):3-7. DOI: 10.1177/1358863X9600100102. View

Breek J, Hamming J, de Vries J, van Berge Henegouwen D, Van Heck G . The impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life in patients with intermittent claudication. J Vasc Surg. 2002; 36(1):94-9. DOI: 10.1067/mva.2002.124369. View

Brass E, Anthony R, Cobb F, Koda I, Jiao J, Hiatt W . The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006; 48(12):2539-45. DOI: 10.1016/j.jacc.2006.07.064. View

Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P . Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol. 2002; 21(1):20-7. View

Kanayama M, Hashimoto T, Shigenobu K, Oha F, Yamane S . New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial. J Neurosurg Spine. 2005; 2(4):441-6. DOI: 10.3171/spi.2005.2.4.0441. View

Boccalon H, Lehert P, Mosnier M . [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. Ann Cardiol Angeiol (Paris). 2003; 50(3):175-82. DOI: 10.1016/s0003-3928(01)00016-6. View

Hara H, Osakabe M, Kitajima A, TAMAO Y, Kikumoto R . MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost. 1991; 65(4):415-20. View

McDermott M, Liu K, Guralnik J, Martin G, Criqui M, Greenland P . Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg. 1998; 28(6):1072-81. DOI: 10.1016/s0741-5214(98)70034-5. View

10.

Myers S, Johanning J, Stergiou N, Lynch T, Longo G, Pipinos I . Claudication distances and the Walking Impairment Questionnaire best describe the ambulatory limitations in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2008; 47(3):550-555. DOI: 10.1016/j.jvs.2007.10.052. View

11.

Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2006; 33 Suppl 1:S1-75. DOI: 10.1016/j.ejvs.2006.09.024. View

12.

Feinglass J, McCarthy W, Slavensky R, Manheim L, Martin G . Effect of lower extremity blood pressure on physical functioning in patients who have intermittent claudication. The Chicago Claudication Outcomes Research Group. J Vasc Surg. 1996; 24(4):503-11; discussion 511-2. DOI: 10.1016/s0741-5214(96)70066-6. View

13.

Nagatomo T, Rashid M, Muntasir H, Komiyama T . Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004; 104(1):59-81. DOI: 10.1016/j.pharmthera.2004.08.005. View

14.

Dormandy J, Rutherford R . Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000; 31(1 Pt 2):S1-S296. View

15.

Money S, HERD J, Isaacsohn J, Davidson M, Cutler B, HECKMAN J . Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998; 27(2):267-74; discussion 274-5. DOI: 10.1016/s0741-5214(98)70357-x. View

16.

Barradas M, Gill D, Fonseca V, Mikhailidis D, Dandona P . Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 1988; 18(4):399-404. DOI: 10.1111/j.1365-2362.1988.tb01030.x. View

17.

Menard J, Smith H, Riebe D, Braun C, Blissmer B, Patterson R . Long-term results of peripheral arterial disease rehabilitation. J Vasc Surg. 2004; 39(6):1186-92. DOI: 10.1016/j.jvs.2004.01.034. View

18.

Mawatari K, Komori K, Kuma S, Yamamura S, Ishii T, Sugimachi K . Effects of serotonin and endothelin on the smooth muscle cells of autogenous vein grafts. Br J Surg. 1997; 84(10):1419-24. View

19.

Regensteiner J, Hargarten M, Rutherford R, Hiatt W . Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology. 1993; 44(1):1-10. DOI: 10.1177/000331979304400101. View

20.

Sharma S, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla N . Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther. 1999; 290(3):1475-81. View